Patents by Inventor Tong Zhu

Tong Zhu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190076438
    Abstract: The present invention provides an anti-ErbB2 antibody-drug conjugate, a composition comprising the conjugate, a method for preparing the conjugate, use of the conjugate.
    Type: Application
    Filed: November 22, 2016
    Publication date: March 14, 2019
    Applicant: SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.
    Inventors: Tongtong XUE, Zhenwei MIAO, Jing WANG, Gang CHEN, Yan QING, Tong ZHU, Liang XIAO, Hong ZHANG, Qiuyan YANG, Dylan Dalun DENG, Liping LIU, Hong ZENG, Li YIN, Qifeng SHI, Hongmei SONG, Xi ZHAO, Lichun WANG, Jingyi WANG
  • Publication number: 20190038764
    Abstract: Provided are bispecific conjugates having the general formula: pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, and their use in the treatment of cancer.
    Type: Application
    Filed: August 1, 2018
    Publication date: February 7, 2019
    Applicant: Sorrento Therapeutics, Inc.
    Inventors: James T. Patterson, Gunnar F. Kaufmann, Yanwen Fu, Tong Zhu
  • Publication number: 20180360985
    Abstract: There is disclosed an antibody drug conjugate (ADC) having an IgG antibody that binds to a CD38 target conjugated at a Cys site in the hinge region of an IgG antibody. There is further disclosed a method for treating multiple myeloma comprising providing an effective amount of a CD38 ADC.
    Type: Application
    Filed: June 20, 2018
    Publication date: December 20, 2018
    Applicant: Sorrento Therapeutics, Inc.
    Inventors: Tong Zhu, Alisher Khasanov, Gang Chen, Katherine Fells
  • Publication number: 20180280531
    Abstract: There is disclosed an antibody drug conjugate (ADC) having an IgG antibody that binds to a c-Met target conjugated at both Cys sites in the hinge region of an IgG antibody. There is further disclosed a method for treating a breast cancer comprising providing an effective amount of a c-Met ADC.
    Type: Application
    Filed: December 8, 2015
    Publication date: October 4, 2018
    Inventors: Tong Zhu, Gang Chen, Yanwen Fu, Edwige Gros
  • Publication number: 20180243438
    Abstract: In one aspect, an active agent-conjugate, methods of preparing the active agent-conjugate, and uses thereof is provided.
    Type: Application
    Filed: December 26, 2017
    Publication date: August 30, 2018
    Applicant: Concortis Biosystems, Corp.
    Inventors: Zhenwei Miao, Yufeng Hong, Tong Zhu, Alexander Wilhelm Chucholowski
  • Publication number: 20180194859
    Abstract: There is disclosed methods for derivatizing and conjugating two hinge-containing antibody molecules. There is further disclosed derivatized and conjugated hinge-containing antibody molecules.
    Type: Application
    Filed: January 12, 2018
    Publication date: July 12, 2018
    Applicant: Sorrento Therapeutics, Inc.
    Inventors: Gunnar F. Kaufmann, Yanwen Fu, James Patterson, Tong Zhu
  • Patent number: 9981046
    Abstract: In one aspect, an active agent-conjugate, methods of preparing the active agent-conjugate, and uses thereof is provided.
    Type: Grant
    Filed: May 14, 2013
    Date of Patent: May 29, 2018
    Assignee: Concortis Biosystems, Corp., a wholly owned subsidiary of Sorrento Therapeutics, Inc.
    Inventors: Zhenwei Miao, Yufeng Hong, Tong Zhu
  • Publication number: 20180085471
    Abstract: In certain aspects, compounds and uses thereof are provided. In certain aspects, compound-conjugates and uses thereof are provided.
    Type: Application
    Filed: August 17, 2017
    Publication date: March 29, 2018
    Inventors: Zhenwei Miao, Yufeng Hong, Tong Zhu
  • Patent number: 9884127
    Abstract: In one aspect, an active agent-conjugate, methods of preparing the active agent-conjugate, and uses thereof is provided.
    Type: Grant
    Filed: May 14, 2013
    Date of Patent: February 6, 2018
    Assignee: Concortis Biosystems, Corp.
    Inventors: Zhenwei Miao, Yufeng Hong, Tong Zhu, Alexander Wilhelm Chucholowski
  • Publication number: 20170340750
    Abstract: There is disclosed derivatives of amanitin conjugated to a targeting antibody to form an ADC (antibody drug conjugate).
    Type: Application
    Filed: May 31, 2017
    Publication date: November 30, 2017
    Inventors: Tong Zhu, Hong Zhang, Alisher B. Khasanov, Gang Chen
  • Patent number: 9801951
    Abstract: In certain aspects, compounds and uses thereof are provided. In certain aspects, compound-conjugates and uses thereof are provided.
    Type: Grant
    Filed: May 14, 2013
    Date of Patent: October 31, 2017
    Assignee: Concortis Biosystems, Corp.
    Inventors: Zhenwei Miao, Yufeng Hong, Tong Zhu
  • Publication number: 20170281758
    Abstract: There is disclosed a calicheamicin antibody drug conjugate comprising a linking amidoacetyl group covalently bound to a sugar moiety on calicheamicin or linking to sulfur atom on calicheamicin through disulfide bond.
    Type: Application
    Filed: March 29, 2017
    Publication date: October 5, 2017
    Inventors: Gang Chen, Alisher B. Khasanov, Hong Zhang, Tong Zhu, Zhenwei Miao
  • Publication number: 20170281796
    Abstract: There is disclosed an antibody drug conjugate (ADC) having an IgG antibody that binds to a c-Met target conjugated at both Cys sites in the hinge region of an IgG antibody. There is further disclosed a method for treating a breast cancer comprising providing an effective amount of a c-Met ADC.
    Type: Application
    Filed: December 8, 2015
    Publication date: October 5, 2017
    Applicant: Sorrento Therapeutics, Inc.
    Inventors: Tong Zhu, Gang Chen, Yanwen Fu, Edwige Gros
  • Publication number: 20170224835
    Abstract: There is disclosed antibody drug conjugates having anthracycline derivative drug moieties that provide improved safety and cell killing efficacy, wherein the anthracycline derivative drug moieties substitute an hydroxymethyl ketone moiety for an hydrazide or hydroxamate moiety. The disclosed cytotoxic agents (i.e., drug moieties) are conjugated to an antibody via either a Cys or a Lys residue. For Lys conjugation, the DAR (drug antibody ratio) of the majority of the ADC is 2 whereas the DAR of the majority of ADC is 4 when conjugation occurs on a Cys residue.
    Type: Application
    Filed: February 5, 2016
    Publication date: August 10, 2017
    Applicant: Sorrento Therapeutics, Inc.
    Inventors: Zhenwei Miao, Gang Chen, Tong Zhu, Alisher B. Khasanov, Dylan Deng, Hong Zhang, Zheng Yan
  • Publication number: 20170190736
    Abstract: There is disclosed a Dolastatin derivative, conjugated to an antibody, comprising a Dolastatin derivative moiety of Formula IV.
    Type: Application
    Filed: January 28, 2016
    Publication date: July 6, 2017
    Applicant: Sorrento Therapeutics, Inc.
    Inventors: Zhenwei Miao, Gang Chen, Tong Zhu, Alisher B. Khasanov, Dylan Deng, Hong Zhang
  • Publication number: 20170019500
    Abstract: A service processing device and method include receiving a service processing request including data interaction processing mode information and account information, and determining, based on the service processing request, one or more data interaction processing mode candidates for executing the service processing request. The data interaction processing mode candidates are determined from a plurality of data interaction processing modes. Each of the data interaction processing modes includes processing parameters, and at least one of the processing parameters is different between different data interaction processing modes. Each of the one or more data interaction processing mode candidates has an associated processing success rate based on a historical processing record of the data interaction processing modes.
    Type: Application
    Filed: July 13, 2016
    Publication date: January 19, 2017
    Inventors: Weijie YAN, Shuangfeng LI, Tong ZHU, Zidong HE, Kai XU
  • Publication number: 20160067350
    Abstract: In one aspect, an active agent-conjugate, methods of preparing the active agent-conjugate, and uses thereof is provided.
    Type: Application
    Filed: May 14, 2013
    Publication date: March 10, 2016
    Applicant: Concortis Biosystems, Corp., a wholly owned subsidiary of Sorrento Therapeutics, Inc.
    Inventors: Zhenwei Miao, Yufeng Hong, Tong Zhu
  • Publication number: 20160017030
    Abstract: The invention provides a liquid aqueous pharmaceutical formulation comprising a human anti-TNFa antibody, or antigen-binding portion thereof, which reduces pain associated with injection in a subject by at least about 50% when compared to injecting an otherwise identical formulation comprising at least one salt and/or at least one buffer. The invention also provides a liquid aqueous pharmaceutical formulation comprising a human anti-TNFa antibody, or antigen-binding portion thereof, having increased bioavailability upon subcutaneous administration into a subject. The formulation may comprise a therapeutic protein, such as a human anti-TNF-alpha antibody, or an antigen-binding portion thereof, or a biosimilar thereof.
    Type: Application
    Filed: July 30, 2015
    Publication date: January 21, 2016
    Inventors: Michael Neu, Markus Tschoepe, Carsten Weber, Wolfgang Fraunhofer, Laura Redden, Martin Gastens, Alexander Feick, Susan K. Paulson, Tong Zhu
  • Publication number: 20150141646
    Abstract: In certain aspects, compounds and uses thereof are provided. In certain aspects, compound-conjugates and uses thereof are provided.
    Type: Application
    Filed: May 14, 2013
    Publication date: May 21, 2015
    Applicant: Concortis Biosystems, Corp., a wholly owned subsidary of Sorrento Therapeutics, Inc,
    Inventors: Zhenwei Miao, Yufeng Hong, Tong Zhu
  • Publication number: 20150105539
    Abstract: In one aspect, an active agent-conjugate, methods of preparing the active agent-conjugate, and uses thereof is provided.
    Type: Application
    Filed: May 14, 2013
    Publication date: April 16, 2015
    Applicant: Concortis Biosystems, Corp., a wholly owned Subsidiary of Sorrento Therapeutics, Inc.
    Inventors: Zhenwei Miao, Yufeng Hong, Tong Zhu, Alexander Wilhelm Chucholowski